Safety and Immunogenicity of a Canarypox‐Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher‐ and Lower‐Risk Volunteers
Open Access
- 1 May 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 183 (9) , 1343-1352
- https://doi.org/10.1086/319863
Abstract
Live attenuated viral vectors that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines to prevent HIV infecKeywords
This publication has 3 references indexed in Scilit:
- HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 VaccineAIDS Research and Human Retroviruses, 1999
- Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteersAIDS, 1998
- Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of InfectionThe Journal of Infectious Diseases, 1993